Anadys Pharmaceuticals INC
SEC CIK 1128495 · ANDS · last insider filing 2011-10-24
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Posner Brian S | Director | filed 2011 - 2011 |
| Papadopoulos Stelios | Director | filed 2006 - 2011 |
| Foletta Mark G | Director | filed 2006 - 2011 |
| Xanthopoulos Kleanthis G | Director · CEO and President | filed 2006 - 2011 |
| Fotiadis Marios | Director | filed 2006 - 2011 |
| Labinger Barry | Director | filed 2011 - 2011 |
| Freddo James L | Director · SVP, Drug Development and CMO | filed 2006 - 2011 |
| Worland Stephen T | Director · President, Pharmaceuticals | filed 2006 - 2010 |
| Scangos George A | Director | filed 2006 - 2010 |
| Holtzman Steven H | Director | filed 2006 - 2010 |
| Williams Douglas E | Director | filed 2006 - 2008 |
| Fritz Lawrence C | Director · President and CEO | filed 2006 - 2007 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Reed Elizabeth E | Vice President, Legal Affairs | filed 2006 - 2011 |
| Slover Peter T | VP, Finance and Operations | filed 2009 - 2011 |
| Eastwood Kevin L. | SVP, Corporate Development | filed 2011 - 2011 |
| Appleman James R. | SVP, Research & CSO | filed 2011 - 2011 |
| Glover James T | SVP, Operations and CFO | filed 2006 - 2008 |
| Yaroshevsky Glanville Mary | Vice President, Human Capital | filed 2006 - 2008 |
| Gallagher Carol Giltner | VP, Corp. Dev. & Comm. Affairs | filed 2007 - 2007 |
| Averett Devron R | Chief Scientific Officer | filed 2006 - 2006 |
| Crittenden Jennifer K | Vice President, Finance | filed 2006 - 2006 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.